

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-517US1	Application No. 10/583,468
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Nafizal Hossain et al.	
		Filing Date June 20, 2006	Group Art Unit 1625

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	US 2007-0249648 A1	10/25/2007	Bladh et al.			
	AB	US-2007-0129393-A1	06/07/2007	Baxter et al.			
	AC	US-2007-0123543-A1	05/31/2007	Hossain et al.			
	AD	US-2007-0099945-A1	05/03/2007	Hossain et al.			
	AE	US-2008-0167332-A1	07/10/2008	Mensonides-Harsema et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AF	WO 2008/010765	01/24/2008	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AG	Brown et al., "Novel CCR1 antagonists with improved metabolic stability", <i>Bioorg. Med. Chem. Lett.</i> 14:2175-2179 (2004)
	AH	Martin et al., "Do Structurally Similar Molecules Have Similar Biological Activity?", <i>J. Med. Chem.</i> 45:4350-4358 (2002)
	AI	Pozharskii et al., <i>Heterocycles in Life and Society</i> . Wiley, 1997, pp. 1-6
	AJ	Thoma et al., "Orally Bioavailable Competitive CCR5 Antagonists", <i>J. Med. Chem.</i> 47:1939-1955 (2004)
	AK	Thomson et al., <i>The Cytokine Handbook</i> , 4 th ed. New York, Academic Press, 2003, pp. 1084-1087
	AL	Ting et al., "The synthesis of substituted biperidine amide compounds as CCR3 ligands: Antagonists versus agonists", <i>Bioorg. Med. Chem. Lett.</i> 15:3020-3023 (2005)
	AM	Xie et al., "Identification of novel series of human CCR1 antagonists", <i>Bioorg. Med. Chem. Lett.</i> 18:2215-2221 (2008)
	AN	
	AO	
	AP	
	AQ	
	AR	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	